20 August 2024 in Clinical Pharmacology & Therapeutics
Ketamine provides the highest safety profile among sedatives for procedural sedation and analgesia in the pediatric emergency setting. However, it can cause vomiting and recovery agitation. No studies have examined epigenetic factors, such as microRNAs, for predicting the occurrence of these adverse events. Neuronal‐derived extracellular vesicle microRNA profiles were studied to predict the occurrence of ketamine‐induced vomiting and recovery agitation in children. For this aim, a single‐center prospective pharmacoepigenetic study was performed and 50 children who underwent procedural sedation with intravenous ketamine as the only sedative drug were enrolled between October 2019 and November 2022. MiRNA profiling in plasma neural‐derived extracellular vesicles was analyzed through next‐generation sequencing and measured before treatment with ketamine. Twenty‐two patients experienced vomiting or recovery agitation. Among the 16 differentially expressed microRNAs, the upregulated miR‐15a‐5p and miR‐484 targeted genes related to N‐methyl‐D‐aspartate (NMDA) receptor activity, including glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A). Preliminary data confirmed lower GRIN2A levels in patients who developed these events. Downregulated miR‐126‐3p and miR‐24‐3p targeted AMPA receptor‐associated genes. Functional analyses of gene targets revealed the enrichment of glutamatergic and neurotrophins signaling. Recovery agitation was associated with this network. Vomiting was related to dopaminergic and cholinergic systems. Three miRNAs (miR‐18a‐3p, miR‐484, and miR‐548az‐5p) were identified as predictive biomarkers (AUC 0.814; 95% CI: 0.632–0.956) for ketamine‐induced vomiting and recovery agitation. MicroRNA profiles can predict the development of ketamine‐induced vomiting or recovery agitation in children. This study contributes to the understanding of the mechanisms underlying ketamine‐induced adverse events.
25 December 2023 in Alzheimer's & Dementia
Background: Stratifying dementia into different subgroups based on specific pathologies can facilitate the development of more effective treatments for subgroups of individuals with dementia. Effective stratification relies on reliable biomarkers. Neuron‐derived extracellular vesicles (NDEs) are lipid structures released by neurons into the extracellular space, and some get into the bloodstream. NDEs carry proteins and RNA that reflect their cell of origin and thus provide a promising biomarker platform.Method: NeuroDex developed two methods. ExoSORT is an optimized NDE isolation platform by immunoaffinity, where NDEs are captured with antibodies against the neuronal‐specific markers GAP43 and NLGN3. LuminEV is an intact extracellular vesicle (EV) immunoassay based on the Luminex platform. Antibodies against a potential biomarker, general EV marker, and IgG (negative control) are multiplexed to generate a robust assay.Result: The vesicular nature and size of NDEs were confirmed by electron microscopy and nanoparticle tracking. EV markers were ascertained by western blot and proteomic analyses, and capture specificity was demonstrated by significantly elevated neuron‐specific proteins and mRNA levels compared to procedural control (IgG). Capture efficiency (∼80%) and precision (CV < 20%) demonstrated recovery of spiked NDEs. Measurements of αSYN following ExoSORT with an MSD assay and on EVs with the LuminEV generated a separation with 83% sensitivity and 86% specificity (45 Parkinson and 30 healthy controls plasma samples). LC3, an autophagy marker, was also measured following ExoSORT and was significantly (P<0.03) elevated in PD and Alzheimer’s disease (AD) (P<0.02, N = 30) plasma samples. TDP43 was also significantly (P<0.004) higher in AD plasma samples following ExoSORT. The synaptic marker GLUR2 was measured by the LuminEV assays and was significantly (P<0.001) reduced in AD and PD plasma samples. Its level was also significantly (P<0.03) correlated with the patient’s cognitive score.Conclusion: Immunoaffinity isolation of EVs from plasma samples according to their cell of origin is a promising biomarker platform. We demonstrate the NDEs isolation selectivity, specificity, and precision. We also show the platform’s potential to identify pathologies like αSYN, TDP43, autophagy, and synaptic dysfunction; this reflects the potential for patient stratification.